← Back to Search

Contrast Agent

Liver MRI with EcGd and with Gdfos for Liver Tumors

N/A
Waitlist Available
Led By Laurent Milot, MD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up participants will receive both gdfos and ecgd study within 4 weeks of each other. radiologist reading for the study will be done up to 52 weeks after first mri has been performed.
Awards & highlights

Study Summary

The purpose of this study is to determine if Gadofosveset Trisodium (Gdfos, Ablavar) is a useful magnetic resonance imaging (MRI) contrast agent in accurately diagnosing liver metastases compared to the standard agent gadobutrol (EcGd, Gadovist).

Eligible Conditions
  • Liver Tumors
  • Cancer
  • Metastasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~participants will receive both gdfos and ecgd study within 4 weeks of each other. radiologist reading for the study will be done up to 52 weeks after first mri has been performed.
This trial's timeline: 3 weeks for screening, Varies for treatment, and participants will receive both gdfos and ecgd study within 4 weeks of each other. radiologist reading for the study will be done up to 52 weeks after first mri has been performed. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Reader diagnostic accuracy using Gdfos vs. EcGd compared to gold standard
Secondary outcome measures
Inter-reader variability for EcGd-enhanced vs. Gdfos-enhanced imaging
Reader diagnostic accuracy of EcGd-enhanced imaging vs. Gdfos-enhanced imaging compared to gold standard (subgroup analysis for small lesions less than or equal to 1cm)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Liver MRI with EcGd and with GdfosExperimental Treatment2 Interventions
All participants will receive two contrast-enhanced MRI studies of the liver: one with gadofosveset trisodium (Gdfos) and one with gadobutrol (EcGd) at a dose of 0.1 mL/kg body mass up to 10 mL.

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
656 Previous Clinical Trials
1,551,157 Total Patients Enrolled
Laurent Milot, MDPrincipal InvestigatorSunnybrook Health Sciences Centre

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial
2013. "Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02036008.
All > Bone Metastases
~13 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top